Literature DB >> 26685070

Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes.

Chia-Feng Yang1, Chen Chang Yang2, Hsuan-Chieh Liao3, Ling-Yi Huang4, Chuan-Chi Chiang5, Hui-Chen Ho6, Chih-Jou Lai7, Tzu-Hung Chu8, Tsui-Feng Yang7, Ting-Rong Hsu8, Wen-Jue Soong8, Dau-Ming Niu9.   

Abstract

OBJECTIVE: To evaluate whether very early treatment in our patients would result in better clinical outcomes and to compare these data with other infantile-onset Pompe disease (IOPD) cohort studies.
METHODS: In this nationwide program, 669,797 newborns were screened for Pompe disease. We diagnosed IOPD in 14 of these newborns, and all were treated and followed in our hospital.
RESULTS: After 2010, the mean age at first enzyme-replacement therapy (ERT) was 11.92 days. Our patients had better biological, physical, and developmental outcomes and lower anti-rh acid α-glucosidase antibodies after 2 years of treatment, even compared with one group that began ERT just 10 days later than our cohort. No patient had a hearing disorder or abnormal vision. The mean age for independent walking was 11.6 ± 1.3 months, the same age as normal children.
CONCLUSIONS: ERT for patients with IOPD should be initiated as early as possible before irreversible damage occurs. Our results indicate that early identification of patients with IOPD allows for the very early initiation of ERT. Starting ERT even a few days earlier may lead to better patient outcomes.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26685070     DOI: 10.1016/j.jpeds.2015.10.078

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  29 in total

Review 1.  Newborn screening: Taiwanese experience.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu; Ni-Chung Lee
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.

Authors:  Ankit K Desai; Cindy Li; Amy S Rosenberg; Priya S Kishnani
Journal:  Ann Transl Med       Date:  2019-07

3.  Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.

Authors:  Mugdha V Rairikar; Laura E Case; Lauren A Bailey; Zoheb B Kazi; Ankit K Desai; Kathryn L Berrier; Julie Coats; Rachel Gandy; Rebecca Quinones; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-09-19       Impact factor: 4.797

4.  Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up.

Authors:  Gail A Spiridigliozzi; Lori A Keeling; Mihaela Stefanescu; Cindy Li; Stephanie Austin; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-05-01       Impact factor: 4.797

Review 5.  The role of patient advocacy organizations in shaping medical research: the Pompe model.

Authors:  Tiffany House; Kevin O'Donnell; Raymond Saich; Fabio Di Pietro; Ria Broekgaarden; Allan Muir; Thomas Schaller
Journal:  Ann Transl Med       Date:  2019-07

6.  Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease.

Authors:  Hsuan-Chieh Liao; Min-Ju Chan; Chia-Feng Yang; Chuan-Chi Chiang; Dau-Ming Niu; Chun-Kai Huang; Michael H Gelb
Journal:  Clin Chem       Date:  2017-04-27       Impact factor: 8.327

7.  Multiplex Lysosomal Enzyme Activity Assay on Dried Blood Spots Using Tandem Mass Spectrometry.

Authors:  Hsuan-Chieh Joyce Liao; Hsiao-Jan Chen
Journal:  Methods Mol Biol       Date:  2022

8.  Targeted Therapies for Metabolic Myopathies Related to Glycogen Storage and Lipid Metabolism: a Systematic Review and Steps Towards a 'Treatabolome'.

Authors:  A Manta; S Spendiff; H Lochmüller; R Thompson
Journal:  J Neuromuscul Dis       Date:  2021

9.  Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.

Authors:  Mrudu Herbert; Laura E Case; Mugdha Rairikar; Heidi Cope; Lauren Bailey; Stephanie L Austin; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2018-08-23       Impact factor: 4.204

Review 10.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.